COMP <GO>
RGEN vs UNH // GROSS PROFIT MARGIN
Repligen Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RGEN 3
— UNH 10
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $172.95 (-2.25%) • MKT CAP: $11.06B
gross-margins
88.20%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 88.20% | 88.31% | -0.11 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 12.38% | -10.08 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.73 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 6.25% | -5.37 | UNH | /fcf-yield <GO> |
| Operating Margin | 1.80% | 5.32% | -3.52 | UNH | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 3.53% | -1.93 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 3.33% | -6.63 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 3.09 | +6.22 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 55.1 | -9.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.33 | +0.71 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.06B | $359.43B | -$348.38B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | UNH REV | RGEN GROSS % | UNH GROSS % | RGEN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $154.5M | $447.57B | — | 88.7% | $93.9M | $16.07B |
| FY 2024 | $98.3M | $400.28B | — | 88.3% | $149.7M | $20.70B |
| FY 2023 | $133.6M | $371.62B | — | 89.6% | $113.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
UNH // BETA 0.33